Drug Trial Radar · NCT06308393
Randomized, Double-blind, Placebo-controlled Study of RSS0393 Ointment in Healthy and Psoriatic Subjects
Last checked: Nov 19, 2026Latest source record: May 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
98
Actual
Start
Mar 1, 2024
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Randomized, double-blind, placebo-controlled study of RSS0393 ointment in healthy and psoriatic subjects
Conditions
- Healthy
- Psoriatic Subjects
Interventions
RSS0393 ointment;PlaceboDrug
RSS0393 ointment;RSS0393 ointment placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percent of Local skin tolerance was assessed as moderate or higher(Single dose in healthy subjects)Time frame: 0.5, 2, 4, 12 post -dose day 1, day 2, day 3, day 5, and day 8
- The percent of Local skin tolerance was assessed as moderate or higher (Multiple dose in healthy subjects)Time frame: 0.5, 2, 4, 12 post-dose day 1, 0.5post-dose on day2、day3、day4、day5、day6, 0.5, 2, 4, 12 post-dose day7, day8, day9, day11, day14
- Measurement of blood examination(Multiple dose in patients )Time frame: Day 1, day 28, day 42 post-dose
- Measurement of urine examination(Multiple dose in patients )Time frame: Day 1, day 28, day 42 post-dose
- Measurement of Blood Chemistry examination(Multiple dose in patients )Time frame: Day 1, day 28, day 42 post-dose
- Measurement of coagulation function examination(Multiple dose in patients )Time frame: Day 1, day 28, day 42 post-dose
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of University of Science and Technology of China (USTC).
Hefei, Anhui, China
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.